Rhumbline Advisers Acquires New Holdings in TransEnterix, Inc. (NYSEAMERICAN:TRXC)
Rhumbline Advisers acquired a new stake in TransEnterix, Inc. (NYSEAMERICAN:TRXC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 142,683 shares of the medical instruments supplier’s stock, valued at approximately $622,000. Rhumbline Advisers owned approximately 0.07% of TransEnterix at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Amalgamated Bank purchased a new position in TransEnterix during the 2nd quarter worth $104,000. Barclays PLC purchased a new stake in shares of TransEnterix in the first quarter valued at about $164,000. Element Capital Management LLC purchased a new stake in shares of TransEnterix in the first quarter valued at about $344,000. Prospera Financial Services Inc boosted its holdings in shares of TransEnterix by 290.9% in the second quarter. Prospera Financial Services Inc now owns 86,000 shares of the medical instruments supplier’s stock valued at $353,000 after acquiring an additional 64,000 shares in the last quarter. Finally, Tibra Equities Europe Ltd purchased a new stake in shares of TransEnterix in the first quarter valued at about $570,000.
Several analysts recently commented on TRXC shares. BTIG Research cut shares of TransEnterix from a “buy” rating to a “neutral” rating in a research note on Thursday, June 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $5.50 price objective on shares of TransEnterix in a research note on Thursday, July 5th. Finally, Zacks Investment Research cut shares of TransEnterix from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th.
TransEnterix (NYSEAMERICAN:TRXC) last posted its quarterly earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $6.39 million for the quarter, compared to analysts’ expectations of $6.20 million. TransEnterix had a negative net margin of 21,045.36% and a negative return on equity of 137.69%.
In other news, Director William N. Starling, Jr. sold 1,700,000 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $6.40, for a total transaction of $10,880,000.00. Following the completion of the transaction, the director now owns 66,987 shares in the company, valued at $428,716.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Joseph P. Slattery sold 124,398 shares of the company’s stock in a transaction dated Thursday, July 19th. The stock was sold at an average price of $5.00, for a total transaction of $621,990.00. The disclosure for this sale can be found here. Insiders have sold 3,033,622 shares of company stock worth $18,893,751 over the last three months.
TransEnterix Company Profile
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Read More: Asset Allocation, Balancing Your Investments
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.